Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucodynamic Effects of Dulaglutide in Japanese T2DM
NCT03315780Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2017
- Primary completion
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Oct 2017; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03315780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315780.